Continuous muscle fibre activity: A case treated with acetazolamide

Journal of Neurology Neurosurgery and Psychiatry

Volumn 64, Issue 2, 1998, Pages 256-258

  Çelebisoy, Neşe ^a   Çolakoǧlu, Zafer ^a   Akbaba, Yaprak ^a   Yüceyar, Nur ^a  

^a EGE UNIVERSITY   (Turkey)

Author keywords

Acetazolamide; Continuous muscle fibre activity syndrome

Indexed keywords

ACETAZOLAMIDE; CARBAMAZEPINE; LAMOTRIGINE; MEXILETINE;

ADULT; ARTICLE; CASE REPORT; CLINICAL FEATURE; ELECTROMYOGRAPHY; FEMALE; HUMAN; MOTOR UNIT; MUSCLE FIBER CONTRACTION; NERVE FIBER; NEUROMUSCULAR DISEASE; PRIORITY JOURNAL;

EID: 0031922498     PISSN: 00223050     EISSN: None     Source Type: Journal    
DOI: 10.1136/jnnp.64.2.256     Document Type: Article

References (19)

1. Isaacs H. A syndrome of continuous muscle fibre activity. J Neurol Neurosurg Psychiatry 1961;24:319-25.
2. Isaacs H. Continuous muscle fibre activity in an Indian male with additional evidence of terminal motor fiber abnormality. J Neurol Neurosurg Psychiatry 1967;30:126-33.
3. Isaacs H, Hefron JJA. The syndrome of continuous muscle fibre activity cured: further studies. J Neurol Neurosurg Psychiatry 1974;37:1231-5 .
4. Catteral WA. Common modes of drug action on sodium channels: local anesthetics, antiarhytmics and anticonvulsants. Trends Pharmacol Sci 1987;8:57-65.
5. Shorvon S. The drug treatment of epilepsy. In: Hopkins A, Shorvon S, Casino G, eds. Epilepsy. London: Chapman and Hall Medical, 1995:171-214.
6. Griggs RC, Engel WK, Resnick JJ. Acetozolamide treatment of hyperkalaemik periodic paralysis. Ann Intern Med 1970; 73:39-48.
7. Vroom FQ, Jorrell MA, Maren TH. Acetozolamide treatment of hypokalaemic periodic paralysis: Probable mechanism of action. Arch Neurol 1975;32:385-92.
8. Jarrell MA, Greer M, Maren TH. The effect of acidosis in hypokalaemic periodic paralysis. Arch Neurol 1976;33:791-3.
9. Riggs JE, Griggs RC, Moxley RT. Dissociation of glucose and potassium arterial-venous differences across the forearm by acetozolamide. Arch Neurol 1984;41:35-8.
10. Trudell RG, Kaiser KK, Griggs RC. Acetozolamide responsive myotonia congenita. Neurology 1987;37:488-91.
11. Ptacek LJ, Tawil R, Griggs RC, et al. Sodium channel mutations in acetozolamide-responsive myotonia congenita, paramyotonia congenita and hyperkalaemic periodic paralysis. Neurology 1994;44:1500-3.
12. Brunt ERP, Van Weerden TW. Familial paroxsymal kinesigenic ataxia and continuous myokymia. Brain 1990; 113:1361-82.
13. Vaamonde J, Artieda J, Obeso JA. Hereditary paroxysmal ataxia with neuromyotonia. Mov Disord 1991;6:180-2.
14. Browne DL, Gancher ST, Nutt JG, et al. Episodic ataxia/myokymia syndrome is associated with point mutations in the human potassium channel gene, KCNA 1. Nat Genet 1994;8:136-40.
15. Sinha S, Newsom-Davis J, Mills K, Byrne N, Lang B, Vincent A. Autoimmune aetiology for aquired neuromyotonia (Isaacs' syndrome). Lancet 1991;338:75-7.
16. Newsom-Davis J, Mills KR. Immunological associations of aquired neuromyotonia (Isaacs' syndrome): report of 5 cases and literature review. Brain 1993;116:453-69 .
17. Shillito P, Molenaar PC, Vincent A, et al. Aquired neuromyotonia: evidence for antibodies directed against potassium channels of peripheral nerves. Ann Neurol 1995; 38:714-22.
18. Wasserstein PH, Shadlen MN, Dolfman LJ. Succesful treatment of neuromyotonia with mexiletine [abstract]. Neurology 1992;42(suppl 3):270.
19. Mertens HG, Zschoke S. Neuromyotonie. Klin Wochenschr 1965;47:280-7.